WO2019194494A1 - 뇌졸중의 예방 또는 치료용 조성물 - Google Patents
뇌졸중의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2019194494A1 WO2019194494A1 PCT/KR2019/003794 KR2019003794W WO2019194494A1 WO 2019194494 A1 WO2019194494 A1 WO 2019194494A1 KR 2019003794 W KR2019003794 W KR 2019003794W WO 2019194494 A1 WO2019194494 A1 WO 2019194494A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stroke
- composition
- present
- formula
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 47
- 230000002265 prevention Effects 0.000 title abstract description 10
- 208000006011 Stroke Diseases 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims description 30
- 235000013305 food Nutrition 0.000 claims description 19
- 230000007659 motor function Effects 0.000 claims description 16
- 239000004480 active ingredient Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 206010061216 Infarction Diseases 0.000 claims description 11
- 230000007574 infarction Effects 0.000 claims description 11
- 238000011084 recovery Methods 0.000 claims description 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims description 2
- 210000002425 internal capsule Anatomy 0.000 claims description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 abstract description 6
- AXIUZWFYRNNIFL-MERQFXBCSA-N methanesulfonic acid (2S)-2-[[4-[4-(trifluoromethyl)phenyl]phenyl]methylamino]propanamide Chemical compound CS(=O)(=O)O.FC(C1=CC=C(C=C1)C1=CC=C(C=C1)CN[C@H](C(=O)N)C)(F)F AXIUZWFYRNNIFL-MERQFXBCSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- -1 (4'-trifluoromethylbiphenyl-4-yl) methyl Chemical group 0.000 description 14
- 206010033799 Paralysis Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 241000283984 Rodentia Species 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CBATUQSECWXTQY-UHFFFAOYSA-N methanesulfonic acid propanamide Chemical compound CCC(N)=O.CS(O)(=O)=O CBATUQSECWXTQY-UHFFFAOYSA-N 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004744 fore-foot Anatomy 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000013307 optical fiber Substances 0.000 description 3
- 208000021090 palsy Diseases 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000011631 stroke animal model Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000033912 thigmotaxis Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Definitions
- the present invention relates to a composition for preventing or treating stroke, and specifically includes (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate It relates to a composition for preventing or treating a stroke, a food composition for preventing or improving a stroke, a feed composition, a method for preventing or treating a stroke, and a use for preventing or treating a stroke of the compound.
- Stroke is a cerebrovascular disease and, along with heart disease and cancer, is the three leading cause of death and one of the most common diseases that affects life expectancy and prolonging the population's age as the frequency increases gradually.
- Hypertension, hyperlipidemia, atherosclerosis, and hypercholesterolemia are known as various important risk factors for cerebrovascular stroke.
- Ischemic stroke which is caused by a decrease in or block of the blood supply to the brain tissue
- hemorrhagic stroke that causes blood vessels to bleed and burst in the brain tissue.
- Ischemic stroke accounts for about 80% of all stroke patients.
- the mortality rate due to stroke is increasing year by year as well as domestically and globally, and much attention is being paid to the development of stroke treatment drugs today.
- Patent Document 1 Korean Registered Patent Publication No. 10-1795562
- Patent Document 2 Korean Patent Publication No. 10-1781060
- the inventors have found that the (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate compound of the present invention restores motor function deterioration due to stroke,
- the present invention was completed by confirming that the effect of reducing the infarct size in the inclusions was useful for the prevention and treatment of stroke.
- One object of the present invention is to provide a pharmaceutical composition for preventing or treating stroke, comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- Still another object of the present invention is to provide a food composition for preventing or improving stroke, comprising the compound as an active ingredient.
- Another object of the present invention is to provide a method for preventing or treating stroke, comprising administering the compound to a subject.
- Another object of the present invention is to provide a use for preventing or treating stroke of the compound.
- composition comprising the compound of formula 1 of the present invention has been found to have an excellent effect on the prevention, improvement and treatment of stroke by restoring the reduced motor function due to stroke and reducing the infarct size.
- the composition comprising can be usefully used to prevent, ameliorate and treat stroke.
- Figure 2 shows the effect of restoring the motor function due to KDS2010 administration in rodent palsy model.
- Figure A shows the overall experimental period and the drug administration time.
- FIG. B is a diagram illustrating a single-pellet reaching task (SPRT) test, and FIGS. C and D show SPRT scores.
- Fig. E shows the cylinder test, and Figs. F and G show the ratios of the use of the forefoot to the opposite side of the total number of times during the cylinder test.
- Stroke stroke model
- Stroke + rehab stroke model with rehabilitation
- Stroke + KDS2010 stroke model with drug administration
- Stroke + rehab + KDS2010 stroke model with drug administration and rehabilitation
- Figure 3 shows the effect of restoring brain tissue damage caused by KDS2010 administration in rodent palsy model.
- One aspect of the present application for achieving the above object provides a pharmaceutical composition for preventing or treating stroke (stroke) comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound represented by Formula 1 is (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate ((S) -2- A compound named (((4'-trifluoromethyl biphenyl-4-yl) methyl) amino) propanamide methanesulfonate).
- the compound may be named KDS2010.
- the present invention is not particularly limited to the method of obtaining (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate and is known in the art. Chemically synthesized or commercially available materials can be used.
- the (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate of the present invention is not only solvated but also unsolvated. It may also exist in the form.
- the (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfonate of the present invention may exist in crystalline or amorphous form, all such physical forms It is included in the scope of the present invention.
- the pharmaceutical composition of the present invention may include a compound represented by Formula 1 as well as a pharmaceutically acceptable salt thereof.
- pharmaceutically acceptable salt refers to a substance in which the compound is in the form of a salt combined with another substance, and which can exhibit pharmaceutically similar activity.
- the pharmaceutically acceptable salts include, but are not limited to, inorganic acid salts such as hydrochloride, hydrobromide, phosphate or sulfate and organic acid salts such as carboxylic acid salts or sulfonic acid salts.
- kinds of carboxylates include, but are not limited to, acetates, maleates, fumarates, malates, citrates, tartarates, lactates or benzoates.
- the type of sulfonate includes, but is not limited to, methane sulfonate, ethane sulfonate, benzene sulfonate, toluene sulfonate, or naphthalenedi sulfonate.
- 'stroke' refers to a symptom of a local neurological deficit suddenly induced by cerebrovascular abnormalities.
- Such strokes may include cerebral infarction, in which cerebrovascular is blocked by blood clots, leading to death of brain cells, or cerebral hemorrhage caused by cerebral blood vessels bursting.
- Specific stroke symptoms include sudden headache and vomiting, paraplegia, paralysis of part of the body, sensory paralysis and loss of part of the body, speech impairment (aphasia or pronunciation disorder), facial neuropathy, ataxia, etc. May appear.
- Stroke in the present invention may mean a stroke.
- the pharmaceutical composition of the present invention may be to promote recovery of impaired motor function due to stroke, or to reduce infarct size.
- composition containing the compound of formula 1 of the present invention has an excellent effect for the prevention or treatment of stroke.
- prevention refers to any action that inhibits or delays the onset of stroke by administration of a composition comprising a compound of Formula 1 of the present invention.
- treatment refers to any action that improves or advantageously alters the symptoms of the disease by administration of a composition comprising a compound of Formula 1 of the present invention.
- compositions for preventing or treating stroke of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection.
- composition for preventing or treating stroke of the present invention may further include a pharmaceutically acceptable carrier.
- compositions for preventing or treating stroke of the present invention may be prepared in pharmaceutical formulations using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the active ingredient is mixed or diluted with the carrier or enclosed in a carrier in the form of a container.
- the composition for preventing or treating stroke of the present invention is in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations, suppositories, and sterile injectable solutions according to conventional methods. It may be formulated and used, and further include suitable carriers, excipients and diluents conventionally used in the preparation of the composition.
- carriers that may be included in the compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which include at least one excipient such as starch, calcium carbonate, sucrose in the compound. Or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Oral liquid preparations include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
- base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can achieve the maximum effect in a minimum amount without causing side effects, and can be easily determined by those skilled in the art.
- the term "administration” means introducing the pharmaceutical composition of the present invention to a patient in any suitable manner, and the route of administration of the composition of the present invention may be varied orally or parenterally as long as it can reach the target tissue. It can be administered via the route.
- the mode of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may be in accordance with methods commonly used in the art.
- the composition may be administered by oral or parenteral administration.
- the pharmaceutical compositions according to the invention may be prepared in various formulations depending on the desired mode of administration.
- the frequency of administration of the composition of the present invention is not particularly limited, but may be administered once a day or several times in divided doses.
- a typical daily dosage of a composition comprising a compound of formula 1 of the present invention as an active ingredient may be administered so as to be administered at 1 to 1,000 mg / kg, specifically 11 to 100 mg / kg, once or several It may be administered in divided doses.
- the present invention provides a food composition for preventing or improving stroke, comprising the compound represented by Chemical Formula 1 as an active ingredient.
- the food composition for preventing or improving a stroke of the present invention includes a form of a pill, powder, granule, acupuncture, tablet, capsule or liquid, and the like to which the composition of the present invention can be added, for example, various foods , For example, drinks, gum, tea, vitamin complexes, dietary supplements and the like.
- compositions or an active ingredient thereof or a physiologically acceptable salt thereof are included in the food composition for preventing or improving stroke of the present invention.
- Herbal extracts, food supplements or natural carbohydrates and the like may be included as additional ingredients.
- food supplement additives which may further be added, include food supplement additives conventional in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
- natural carbohydrates examples include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents for example, rebaudioside A, glycyrrhizin, etc.
- synthetic flavoring agents sacharin, aspartame, etc.
- the food composition for preventing or improving stroke of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors such as flavoring agents, colorants and neutralizing agents (such as cheese, chocolate), pectic acid and Salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. Others may contain pulp for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components can be used independently or in combination.
- the health supplement food in the present invention includes a health functional food and health food.
- the functional food is the same term as food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, medical treatment has a high effect Means food.
- the term “functionality” means obtaining useful effects for health purposes such as nutrient control or physiological action on the structure and function of the human body.
- the food of the present invention may be prepared by a method commonly used in the art, and the preparation may be performed by adding raw materials and ingredients commonly added in the art.
- the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
- Food composition of the present invention can be prepared in various forms of formulation, unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material, and excellent portability, the present invention Foods can be taken as a supplement to enhance the effects of preventing or improving stroke.
- the present invention provides a feed composition for preventing or improving stroke, comprising the compound represented by Chemical Formula 1 as an active ingredient.
- the feed composition of the present invention may mean any natural or artificial diet, one meal, or the like or a component of the one meal for the animal to eat, ingest, digest, or suitable for, and in various forms known in the art. It is possible to manufacture.
- the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
- Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
- the feed additive composition of the present invention in addition to the compounds described above for administration, in addition to organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, phosphates such as potassium phosphate, sodium phosphate, polymerized phosphate, polyphenols, catechin, tocopherol,
- organic acids such as citric acid, fumaric acid, adipic acid, lactic acid, phosphates such as potassium phosphate, sodium phosphate, polymerized phosphate, polyphenols, catechin, tocopherol
- phosphates such as potassium phosphate, sodium phosphate, polymerized phosphate, polyphenols, catechin, tocopherol
- One or more components of natural antioxidants such as vitamin C, green tea extract, chitosan and tannic acid may be mixed and used, and other conventional additives such as buffers and bacteriostatic agents may be added as necessary. It can also be formulated by adding additional diluents, dispersants, surfactants
- the feed composition is. It can be easily administered directly in animal feed or in combination with other ingredients. Dosage varies in range depending on the animal's weight, health condition, diet, method of administration and severity of disease.
- the present invention provides a method for preventing or treating stroke, comprising administering a compound represented by Formula 1 to a subject.
- the prevention or treatment method may further include a rehabilitation step.
- the term "individual” may refer to any animal, including humans, who are or may have a stroke.
- the animal may be a mammal such as, but not limited to, a human, a cow, a horse, a sheep, a pig, a goat, a camel, a antelope, a dog, a cat, and the like, which require treatment of similar symptoms.
- the prophylactic or therapeutic method of the present invention may specifically include administering the composition in a pharmaceutically effective amount to a subject having or at risk of developing a stroke.
- the present invention provides a use of the compound represented by the formula (1) for the prevention or treatment of stroke.
- the compound or the prevention or treatment of stroke is as described above.
- Subject drugs were prepared to confirm that they had a therapeutic effect on stroke.
- the drug to be administered was prepared as described in Korean Patent Publication No. 10-1746060.
- (S) -2-(((4'-trifluoromethylbiphenyl-4-yl) methyl) amino) propanamide methanesulfo described in Example 9 of the publication Nate (hereinafter KDS2010) was synthesized.
- a white matter cerebral infarct animal model was produced by photostimulation to the posterior limb of the internal capsule of 9-week-old SD rats.
- ketamine hydrochloride 100 mg / kg
- xylazine 7 mg / kg
- stereotaxis A hole was inserted at a position of 2.0 mm and a side of 3.1 mm, and an optical fiber (inner diameter 62.5 ⁇ m, outer diameter 125 ⁇ m) was inserted to a depth of 7.2 mm to target the nested olfactory.
- Rose Bengal Rose Bengal, 20 mg / kg
- ketoprofen (2 mg / kg) for pain control, it was recovered.
- the control group was injected with 0.9% saline instead of rose bengal.
- the brain structure of the manufactured cerebral infarction animal model is shown in FIG. 1.
- mice in the group administered KDS2010 with the drug were taken orally once daily to dissolve KDS2010 in saline and take a concentration of 10 mg / kg (FIG. 2A).
- the animals were placed in transparent cylinders (20 cm in diameter and 30 cm in height) and their feet were used to support the cylinder wall with their forefoots. A total of 20 movements were recorded to calculate the percentage of use of the forefoot on the opposite side and the front side of the stroke.
- the single-pellet reaching task used an acrylic box (45 cm ⁇ 13 cm ⁇ 40 cm) with a 1 cm longitudinal slit on the front wall, with sugar pellets in front of the slit. Animals were prepared to fast food until they reached 90% of their weight. The percentage of the total 20 pellets taken without dropping them was calculated.
- nerve fibers were stained using the extracted brain tissue, nerve fiber (neurofilament) antibody (SMI-31R, BioLegend, CA, USA) and DAB staining kit (TL-060-QHD, Thermo, MA, USA).
- the nerve fibers were stained as in the method of Example 1-5 to observe the infarct size in the inclusions.
- KDS2010 can reduce the infarct area, restore motor function, and prevent and treat stroke, ie stroke.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Pediatric Medicine (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (8)
- 제1항에 있어서, 상기 뇌졸중은 허혈성 뇌졸중(ischemic stroke) 또는 출혈성 뇌졸중(ischemic stroke)인 것인, 조성물.
- 제1항에 있어서, 상기 조성물은 뇌졸중으로 인해 감소된 운동 기능의 회복을 촉진하는 것을 특징으로 하는 것인, 조성물.
- 제1항에 있어서, 상기 조성물은 내포(internal capsule)에서의 경색(infarction) 크기를 감소시키는 것을 특징으로 하는 것인, 조성물.
- 제6항에 있어서, 재활훈련 단계를 추가로 포함하는, 뇌졸중의 예방 또는 치료방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/045,409 US20210401782A1 (en) | 2018-04-04 | 2019-04-01 | Composition for preventing and treatment of stroke |
AU2019248198A AU2019248198A1 (en) | 2018-04-04 | 2019-04-01 | Composition for prevention or treatment of stoke |
CN201980024643.0A CN111936128B (zh) | 2018-04-04 | 2019-04-01 | 脑卒中的预防或治疗用组合物 |
EP19781046.8A EP3777848B1 (en) | 2018-04-04 | 2019-04-01 | Composition for prevention or treatment of stroke |
JP2020544616A JP6930037B2 (ja) | 2018-04-04 | 2019-04-01 | 脳卒中の予防又は治療用組成物 |
CA3090782A CA3090782C (en) | 2018-04-04 | 2019-04-01 | Composition for preventing or treatment of stroke |
BR112020016920-0A BR112020016920A2 (pt) | 2018-04-04 | 2019-04-01 | Composição farmacêutica para prevenção ou tratamento de um acidente vascular cerebral, composição alimentar para prevenção ou mitigação de um acidente vascular cerebral e método para prevenção ou tratamento de um acidente vascular cerebral |
RU2020130021A RU2765151C1 (ru) | 2018-04-04 | 2019-04-01 | Композиция для предотвращения или лечения инсульта |
AU2021225169A AU2021225169A1 (en) | 2018-04-04 | 2021-08-31 | Composition for prevention or treatment of stroke |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180039368A KR102005019B1 (ko) | 2018-04-04 | 2018-04-04 | 뇌졸중의 예방 및 치료용 조성물 |
KR10-2018-0039368 | 2018-04-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019194494A1 true WO2019194494A1 (ko) | 2019-10-10 |
Family
ID=67473806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/003794 WO2019194494A1 (ko) | 2018-04-04 | 2019-04-01 | 뇌졸중의 예방 또는 치료용 조성물 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210401782A1 (ko) |
EP (1) | EP3777848B1 (ko) |
JP (1) | JP6930037B2 (ko) |
KR (1) | KR102005019B1 (ko) |
CN (1) | CN111936128B (ko) |
AU (2) | AU2019248198A1 (ko) |
BR (1) | BR112020016920A2 (ko) |
CA (1) | CA3090782C (ko) |
RU (1) | RU2765151C1 (ko) |
WO (1) | WO2019194494A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102427769B1 (ko) * | 2020-08-07 | 2022-08-02 | 한국과학기술연구원 | 다발성 경화증 예방 또는 치료용 조성물 |
KR102578811B1 (ko) * | 2020-08-26 | 2023-09-14 | 주식회사 뉴롤메드 | 소브레롤을 유효성분으로 함유하는 허혈성 뇌졸중 예방 또는 치료용 조성물 |
KR102531540B1 (ko) * | 2020-09-18 | 2023-05-16 | 한국과학기술연구원 | 류마티스 관절염 예방 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060010745A (ko) * | 2003-04-11 | 2006-02-02 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 파킨슨병의 치료방법 |
KR20090018817A (ko) * | 2006-06-15 | 2009-02-23 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 인지 장애의 치료에 유용한 알파-아미노아미드 유도체 |
US20140235580A1 (en) * | 2011-09-29 | 2014-08-21 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
KR20160039817A (ko) * | 2014-10-02 | 2016-04-12 | 한국과학기술연구원 | 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물 |
US20160137592A1 (en) * | 2008-03-19 | 2016-05-19 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
CA2859129C (en) | 2011-12-27 | 2020-07-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating epilepsy |
EP2970125B1 (en) * | 2013-03-14 | 2018-07-18 | Dart Neuroscience (Cayman) Ltd. | Substituted naphthyridine and quinoline compounds as mao inhibitors |
WO2016044635A1 (en) * | 2014-09-17 | 2016-03-24 | Dart Neuroscience, Llc | Mao-b inhibitors and rehabilitation |
KR101746060B1 (ko) * | 2015-09-18 | 2017-06-12 | 한국과학기술연구원 | 항비만 치료용 가역적 마오비 저해제 |
AU2015324914B2 (en) * | 2014-10-02 | 2018-10-04 | Neurobiogen Co., Ltd. | Alpha-aminoamide derivative compound and pharmaceutical composition containing the same |
KR101781060B1 (ko) | 2016-02-23 | 2017-09-25 | 주식회사 레스코퍼레이션 | 허혈성 뇌졸중의 치료 및 예방용 약학 조성물 |
JP6842512B2 (ja) * | 2019-07-31 | 2021-03-17 | 本田技研工業株式会社 | 車体の後部構造 |
-
2018
- 2018-04-04 KR KR1020180039368A patent/KR102005019B1/ko active IP Right Grant
-
2019
- 2019-04-01 EP EP19781046.8A patent/EP3777848B1/en active Active
- 2019-04-01 BR BR112020016920-0A patent/BR112020016920A2/pt unknown
- 2019-04-01 JP JP2020544616A patent/JP6930037B2/ja active Active
- 2019-04-01 US US17/045,409 patent/US20210401782A1/en active Pending
- 2019-04-01 CA CA3090782A patent/CA3090782C/en active Active
- 2019-04-01 WO PCT/KR2019/003794 patent/WO2019194494A1/ko active Application Filing
- 2019-04-01 AU AU2019248198A patent/AU2019248198A1/en not_active Abandoned
- 2019-04-01 CN CN201980024643.0A patent/CN111936128B/zh active Active
- 2019-04-01 RU RU2020130021A patent/RU2765151C1/ru active
-
2021
- 2021-08-31 AU AU2021225169A patent/AU2021225169A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060010745A (ko) * | 2003-04-11 | 2006-02-02 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 파킨슨병의 치료방법 |
KR20090018817A (ko) * | 2006-06-15 | 2009-02-23 | 뉴론 파마슈티칼즈 에스. 피. 에이. | 인지 장애의 치료에 유용한 알파-아미노아미드 유도체 |
US20160137592A1 (en) * | 2008-03-19 | 2016-05-19 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
US20140235580A1 (en) * | 2011-09-29 | 2014-08-21 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
KR20160039817A (ko) * | 2014-10-02 | 2016-04-12 | 한국과학기술연구원 | 알파-아미노아미드 유도체 화합물 및 이를 포함하는 약학적 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3777848A4 * |
Also Published As
Publication number | Publication date |
---|---|
CA3090782A1 (en) | 2019-10-10 |
EP3777848B1 (en) | 2024-03-13 |
CN111936128B (zh) | 2022-08-12 |
CA3090782C (en) | 2022-12-06 |
AU2021225169A1 (en) | 2021-09-30 |
AU2019248198A1 (en) | 2020-09-03 |
RU2765151C1 (ru) | 2022-01-26 |
JP6930037B2 (ja) | 2021-09-01 |
EP3777848A1 (en) | 2021-02-17 |
US20210401782A1 (en) | 2021-12-30 |
EP3777848C0 (en) | 2024-03-13 |
JP2021510728A (ja) | 2021-04-30 |
KR102005019B1 (ko) | 2019-07-31 |
CN111936128A (zh) | 2020-11-13 |
BR112020016920A2 (pt) | 2020-12-15 |
EP3777848A4 (en) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019194494A1 (ko) | 뇌졸중의 예방 또는 치료용 조성물 | |
US8841348B2 (en) | Anti-inflammatory formulation | |
WO2020149647A1 (ko) | 페디오코쿠스 이노피나투스를 포함하는 퇴행성 뇌질환의 예방, 개선 또는 치료용 조성물 | |
WO2020040432A1 (ko) | 인삼열매 추출물을 유효성분으로 함유하는 근육 질환의 예방 또는 치료용 약학적 조성물 | |
KR20230018351A (ko) | 렘데시비르와 면역조절제 병용투여법을 통한 자가면역류마티스 질환 치료용 조성물 | |
WO2017073849A1 (ko) | 톱니모자반 추출물을 유효성분으로 포함하는 관절염 예방 또는 치료용 조성물 | |
WO2019156465A1 (ko) | 척수 손상의 예방 및 치료용 조성물 | |
WO2023239016A1 (ko) | 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물 | |
KR102037944B1 (ko) | 무메푸랄을 포함하는 인지장애 관련 질환의 예방 또는 치료용 조성물 | |
WO2018030650A1 (ko) | 국화잎 추출물을 유효성분으로 포함하는 항비만 조성물 | |
WO2020231030A2 (ko) | 락토바실러스 아시도필루스를 포함하는 갱년기 여성의 신경과민, 개미환각, 불면증, 현기증, 또는 피로의 예방, 개선, 또는 치료용 조성물 | |
WO2022225297A1 (ko) | 악액질의 예방, 개선 또는 치료용 조성물 | |
WO2021225343A1 (ko) | 붓꽃 추출물을 포함하는 인지장애의 예방 또는 치료용 조성물 | |
WO2021177660A1 (ko) | 오에노테인 b 유사체를 유효성분으로 포함하는 체중 감량용 조성물 | |
WO2018030838A1 (ko) | 락토바실러스 인테스티날리스를 포함하는 갱년기 예방 또는 치료용 조성물 | |
WO2023075285A1 (ko) | 이미다조피리딘 구조를 포함하는 화합물을 유효성분으로 포함하는 그레이브스병의 예방 또는 치료용 조성물 | |
WO2021066431A1 (ko) | 석류 유래 세포외 소포체 및 이의 용도 | |
WO2024143582A1 (ko) | 바이구아나이드 화합물 기반 관절질환 치료용 주사 치료제 조성물 | |
WO2024143583A1 (ko) | 골관절염 관절강 면역조절 주사 치료제 조성물 | |
WO2021066429A9 (ko) | 마 유래 세포외 소포체 및 이의 용도 | |
WO2024038934A1 (ko) | 오스모틴 단백질을 유효성분으로 함유하는 파킨슨병의 예방, 개선 또는 치료용 조성물 | |
WO2023224305A1 (ko) | 갯까치수염 추출물을 유효성분으로 함유하는 관절염 및 관절통증의 예방, 개선 또는 치료용 조성물 | |
KR102427769B1 (ko) | 다발성 경화증 예방 또는 치료용 조성물 | |
WO2021158046A1 (ko) | 고시폴, 또는 이의 유도체를 유효성분으로 포함하는 신경질환 예방 또는 치료용 약학조성물 | |
WO2024122768A1 (ko) | 복령 추출물을 포함하는 불면증 예방 또는 개선용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19781046 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3090782 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020544616 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019248198 Country of ref document: AU Date of ref document: 20190401 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020016920 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2020130021 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2019781046 Country of ref document: EP Effective date: 20201104 |
|
ENP | Entry into the national phase |
Ref document number: 112020016920 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200819 |